内科理论与实践

内科理论与实践 >

2024 , Vol. 19 >Issue 01: 13 - 18

DOI: https://doi.org/10.16138/j.1673-6087.2024.01.03

专家论坛

糖尿病合并肺部感染临床诊治中需要关注的问题

  • 郑晓燕 ,
  • 易华华 ,
  • 周敏
展开
  • 1.上海交通大学医学院附属瑞金医院舟山分院呼吸与危重症医学科，浙江 舟山 316000
    2.上海交通大学医学院附属瑞金医院呼吸与危重症医学科，上海 200025
周 敏 E-mail：doctor_zhou_99@163.com

收稿日期: 2024-01-16

  网络出版日期: 2024-04-28

基金资助

2021年高水平地方高校创新团队

收起

Issues requiring attention in clinical diagnosis and treatment of diabetes mellitus combined with pulmonary infection

  • ZHENG Xiaoyan ,
  • YI Huahua ,
  • ZHOU Min
Expand
  • 1. Department of Pulmonary and Critical Care Medicine, Zhoushan Branch of Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Zhoushan 316000, China
    2. Department of Pulmonary and Critical Care Medicine, Ruijin Hospital，Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China

Received date: 2024-01-16

  Online published: 2024-04-28

Fold

摘要

糖尿病患病率呈逐年增长趋势。糖尿病患者肺部感染风险较非糖尿病人群明显增加，合并糖尿病的肺部感染患者临床特征、预后亦不同于无糖尿病人群。认识糖尿病患者发生肺部感染的可能机制，熟知糖尿病人群发生细菌、真菌、病毒感染的临床表现，提高临床诊疗水平极其重要。

关键词： 糖尿病; 肺部感染; 病原菌

本文引用格式

郑晓燕 , 易华华 , 周敏 . 糖尿病合并肺部感染临床诊治中需要关注的问题[J]. 内科理论与实践, 2024 , 19(01) : 13 -18 . DOI: 10.16138/j.1673-6087.2024.01.03

Abstract

The prevalence of diabetes is increasing and the risk of pulmonary infection among patients with diabetes mellitus is higher than that among people without diabetes mellitus. The clinical characteristics and prognosis of pulmonary infection patients with diabetic are also distinct from that of patients without diabetic. To improve the level of clinical diagnosis and treatment, it’s important to understand the mechanisms of pulmonary infection in diabetic patients and to be familiar with the clinical manifestations of bacterial, fungal and viral infections in them.

Key words： Diabetes; Pulmonary infection; Pathogenic bacteria

参考文献

[1] Kim EJ, Ha KH, Kim DJ, et al. Diabetes and the risk of infection[J]. Diabetes Metab J, 2019, 43(6):804-814.
[2] Kornum JB, Thomsen RW, Riis A, et al. Type 2 diabetes and pneumonia outcomes[J]. Diabetes Care, 2007, 30(9): 2251-2257.
[3] Sunahara KK, Martins JO. Alveolar macrophages in diabetes: friends or foes?[J]. J Leukoc Biol, 2012, 91(6):871-876.
[4] Alexiewicz JM, Kumar D, Smogorzewski M, et al. Polymorphonuclear leukocytes in non-insulin-dependent diabetes mellitus: abnormalities in metabolism and function[J]. Ann Intern Med, 1995, 123(12):919-924.
[5] Cluxton D, Petrasca A, Moran B, et al. Differential regulation of human treg and Th17 cells by fatty acid synthesis and glycolysis[J]. Front Immunol, 2019, 10:115.
[6] Price CL, Hassi HO, English NR, et al. Methylglyoxal modulates immune responses[J]. J Cell Mol Med, 2010, 14(6B):1806-1815.
[7] Nakayama M, Sugiyama Y, Yamasawa H, et al. Effect of hochuekkito on alveolar macrophage inflammatory responses in hyperglycemic mice[J]. Inflammation, 2012, 35(4):1294-1301.
[8] World Health Organization. The top 10 causes of death[EB/OL]. 2020. https://www.who.int/en/news-room/fact-sheets/detail/the-top-10-causes-of-death.
[9] Olson G, Davis AM. Diagnosis and treatment of adults with community-acquired pneumonia[J]. JAMA, 2020, 323(9):885-886.
[10] Ewig S, Birkner N, Strauss R, et al. New perspectives on community-acquired pneumonia in 388 406 patients. Results from a nationwide mandatory performance measurement programme in healthcare quality[J]. Thorax, 2009, 64(12):1062-1069.
[11] Rivero-Calle I, Cebey-López M, Pardo-Seco J, et al. Lifestyle and comorbid conditions as risk factors for community-acquired pneumonia in outpatient adults (NEUMOES-RISK project)[J]. BMJ Open Respir Res, 2019, 6(1):e000359.
[12] Torres A, Blasi F, Dartois N, et al. Which individuals are at increased risk of pneumococcal disease and why? Impact of COPD, asthma, smoking, diabetes, and/or chronic heart disease on community-acquired pneumonia and invasive pneumococcal disease[J]. Thorax, 2015, 70(10):984-989.
[13] Lim WS, van der Eerden MM, Laing R, et al. Defining community acquired pneumonia severity on presentation to hospital[J]. Thorax, 2003, 58(5):377-382.
[14] Falguera M, Pifarre R, Martin A, et al. Etiology and outcome of community-acquired pneumonia in patients with diabetes mellitus[J]. Chest, 2005, 128(5): 3233-3239.
[15] 金丽媛, 傅方洁, 程思珺, 等. 糖尿病患者免疫功能状态对肺部感染的影响[J]. 医学综述, 2020, 26(18):3674-3678.
[16] 王芳, 刘琼, 范久波, 等. 不同病程的糖尿病患者合并肺部感染病原菌分布及耐药性比较[J]. 中国感染控制杂志, 2019, 18(10):910-916.
[17] Tamer A, Karabay O, Ekerbicer H. Staphylococcus aureus nasal carriage and associated factors in type 2 diabetic patients[J]. Jpn J Infect Dis, 2006, 59(1):10-14.
[18] Philips BJ, Redman J, Brennan A, et al. Glucose in bronchial aspirates increases the risk of respiratory MRSA in intubated patients[J]. Thorax, 2005, 60(9):761-764.
[19] Garnett JP, Baker EH, Naik S, et al. Metformin reduces airway glucose permeability and hyperglycaemia-induced Staphylococcus aureus load independently of effects on blood glucose[J]. Thorax, 2013, 68(9):835-845.
[20] Thurlow LR, Stephens AC, Hurley KE, et al. Lack of nutritional immunity in diabetic skin infections promotes Staphylococcus aureus virulence[J]. Sci Adv, 2020, 6(46):eabc5569.
[21] Zhang QR, Chen H, Liu B, et al. Methicillin-resistant Staphylococcus aureus pneumonia in diabetics[J]. Chin Med J (Engl), 2019, 132(12):1429-1434.
[22] Thaiss CA, Levy M, Grosheva I, et al. Hyperglycemia drives intestinal barrier dysfunction and risk for enteric infection[J]. Science, 2018, 359(6382):1376-1383.
[23] Lee SS, Chen YS, Tsai HC, et al. Predictors of septic metastatic infection and mortality among patients with Klebsiella pneumoniae liver abscess[J]. Clin Infect Dis, 2008, 47(5):642-650.
[24] Huang YT, Jiang JY, Hsu MS, et al. The prevalence of rectal carriage of Klebsiella pneumoniae amongst diabetic patients and their clinical relevance in Taiwan[J]. J Microbiol Immunol Infect, 2018, 51(4):510-518.
[25] Liu YM, Li BB, Zhang YY, et al. Clinical and molecular characteristics of emerging hypervirulent Klebsiella pneumoniae bloodstream infections in mainland China[J]. Antimicrob Agents Chemother, 2014, 58(9):5379-5385.
[26] Choby JE, Howard-Anderson J, Weiss DS. Hypervirulent Klebsiella pneumoniae - clinical and molecular perspectives[J]. J Intern Med, 2020, 287(3):283-300.
[27] World Health Organization. Collaborative framework for care and control of tuberculosis and diabetes[M]. Geneva: World Health Organization, 2011:3.
[28] Chen H, Su L, Bao J, et al. The impact of pulmonary tuberculosis on immunological and metabolic features of diabetic patients[J]. Front Immunol, 2022, 13:973991.
[29] Lee CH, Wang JY, Lin HC, et al. Treatment delay and fatal outcomes of pulmonary tuberculosis in advanced age[J]. BMC Infect Dis, 2017, 17(1):449.
[30] World Health Organization. WHO consolidated guidelines on tuberculosis. Module 4: treatment - drug-resistant tuberculosis treatment[EB/OL]. 2022. https://iris.who.int/bitstream/handle/10665/311389/9789241550529-eng.pdf?ua=1.
[31] Noubiap JJ, Nansseu JR, Nyaga UF, et al. Global prevalence of diabetes in active tuberculosis: a systematic review and meta-analysis of data from 2·3 million patients with tuberculosis[J]. Lancet Glob Health, 2019, 7(4):e448-e460.
[32] Nakamura A, Hagiwara E, Hamai J, et al. Impact of underlying diabetes and presence of lung cavities on treatment outcomes in patients with pulmonary tuberculosis[J]. Diabet Med, 2014, 31(6):707-713.
[33] Salindri AD, Kipiani M, Kempker RR, et al. Diabetes reduces the rate of sputum culture conversion in patients with newly diagnosed multidrug-resistant tuberculosis[J]. Open Forum Infect Dis, 2016, 3(3):ofw126.
[34] Huangfu P, Ugarte-Gil C, Golub J, et al. The effects of diabetes on tuberculosis treatment outcomes: an updated systematic review and meta-analysis[J]. Int J Tuberc Lung Dis, 2019, 23(7):783-796.
[35] 刘又宁, 佘丹阳, 孙铁英, 等. 中国1998年至2007年临床确诊的肺真菌病患者的多中心回顾性调查[J]. 中华结核和呼吸杂志, 2011, 34(2):86-90.
[36] Gong Y, Li C, Wang C, et al. Epidemiology and mortality-associated factors of invasive fungal disease in elderly patients[J]. Infect Drug Resist, 2020, 13:711-723.
[37] Ghanaat F, Tayek JA. Weight loss and diabetes are new risk factors for the development of invasive aspergillosis infection in non-immunocompromized humans[J]. Clin Pract (Lond), 2017, 14(5 Spec Iss):296-301.
[38] Xu H, Li L, Huang WJ, et al. Invasive pulmonary aspergillosis in patients with chronic obstructive pulmonary disease[J]. Clin Microbiol Infect, 2012, 18(4):403-408.
[39] Maitre T, Cottenet J, Godet C, et al. Chronic pulmonary aspergillosis: prevalence, favouring pulmonary diseases and prognosis[J]. Eur Respir J, 2021, 58(2):2003345.
[40] Archuleta S, Gharamti AA, Sillau S, et al. Increased mortality associated with uncontrolled diabetes mellitus in patients with pulmonary cryptococcosis[J]. Ther Adv Infect Dis, 2021, 20499361211004367.
[41] Jeong W, Keighley C, Wolfe R, et al. The epidemiology and clinical manifestations of mucormycosis[J]. Clin Microbiol Infect, 2019, 25(1):26-34.
[42] Chakrabarti A, Das A, Mandal J, et al. The rising trend of invasive zygomycosis in patients with uncontrolled diabetes mellitus[J]. Med Mycol, 2006, 44(4):335-342.
[43] Lin E, Moua T, Limper AH. Pulmonary mucormycosis[J]. Infection, 2017, 45(4):443-448.
[44] Skiada A, Pagano L, Groll A, et al. Zygomycosis in Europe: analysis of 230 cases accrued by the registry of the European Confederation of Medical Mycology (ECMM) Working Group on Zygomycosis between 2005 and 2007[J]. Clin Microbiol Infect, 2011, 17(12):1859-1867.
[45] Qu J, Zhang J, Chen Y, et al. Aetiology of severe community acquired pneumonia in adults identified by combined detection methods[J]. Emerg Microbes Infect, 2022, 11(1):556-566.
[46] Liu YN, Zhang YF, Xu Q, et al. Infection and co-infection patterns of community-acquired pneumonia in patients of different ages in China from 2009 to 2020[J]. Lancet Microbe, 2023, 4(5):e330-e339.
[47] Codo AC, Davanzo GG, Monteiro LB, et al. Elevated glucose levels favor SARS-CoV-2 infection and monocyte response through a HIF-1alpha/glycolysis-dependent axis[J]. Cell Metab, 2020, 32(3):437-446.
[48] Boutin S, Hildebrand D, Boulant S, et al. Host factors facilitating SARS-CoV-2 virus infection and replication in the lungs[J]. Cell Mol Life Sci, 2021, 78(16):5953-5976.
[49] Kusmartseva I, Wu W, Syed F, et al. Expression of SARS-CoV-2 entry factors in the pancreas of normal organ donors and individuals with COVID-19[J]. Cell Metab, 2020, 32(6):1041-1051.
[50] Ji N, Zhang M, Ren L, et al. SARS-CoV-2 in the pancreas and the impaired islet function in COVID-19 patients[J]. Emerg Microbes Infect, 2022, 11(1):1115-1125.
[51] Guo W, Li M, Dong Y, et al. Diabetes is a risk factor for the progression and prognosis of COVID-19[J]. Diabetes Metab Res Rev, 2020, 36(7):e3319.
[52] Chai XQ, Hu LF, Zhang Y, et al. Specific ACE2 expression in cholangiocytes may cause liver damage after 2019-nCoV infection[EB/J]. BioRxiv, 2020..
[53] Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study[J]. Lancet, 2020, 395(10223):507-513.
[54] Hartmann-Boyce J, Morris E, Goyder C, et al. Diabetes and COVID-19: risks, management, and learnings from other national disasters[J]. Diabetes Care, 2020, 43(8):1695-1703.
[55] Zhu L, She ZG, Cheng X, et al. Association of blood glucose control and outcomes in patients with COVID-19 and pre-existing type 2 diabetes[J]. Cell Metab, 2020, 31(6):1068-1077.
[56] Yi H, Lu F, Jin X, et al. Clinical characteristics and outcomes of coronavirus disease 2019 infections among diabetics[J]. J Diabetes, 2020, 12(12):919-928.
[57] Kornum JB, Thomsen RW, Riis A, et al. Diabetes, glycemic control, and risk of hospitalization with pneumonia[J]. Diabetes Care, 2008, 31(8):1541-1545.
[58] Dryden M, Baguneid M, Eckmann C, et al. Pathophysiology and burden of infection in patients with diabetes mellitus and peripheral vascular disease[J]. Clin Microbiol Infect, 2015, 21 Suppl 2:S27-S32.
[59] 中华医学会呼吸病学分会感染学组. 糖尿病合并肺炎诊治路径中国专家共识[J]. 中华结核和呼吸杂志, 2020, 43(8):639-647.
[60] van Crevel R, Koesoemadinata R, Hill PC, et al. Clinical management of combined tuberculosis and diabetes[J]. Int J Tuberc Lung Dis, 2018, 22(12):1404-1410.
Options
文章导航

/

〈 〉